摘要
目的:研究肿瘤坏死因子受体(tumor necrosis factor receptor,TNFR)p55和p75在甲状腺癌组织中的表达及其与临床病理因素之间的关系,从而探索两型受体在甲状腺癌组织中的作用及意义。方法:应用免疫组织化学SP法检测41例甲状腺癌中TNFRp55和TNFRp75的表达情况,并以9例甲状腺腺瘤及7例腺瘤旁形态学正常的甲状腺组织作为对照。结果:①甲状腺癌组织中TNFRp55和TNFRp75的表达水平显著高于甲状腺腺瘤组及正常甲状腺组(P<0.001),而它们在甲状腺腺瘤和正常甲状腺组织中的表达水平无显著性差异(P>0.05)。②两型受体的表达与甲状腺癌的组织学类型密切相关,在乳头状癌组织中的表达水平高于滤泡状癌组织(TNFRp55,P<0.05;TNFRp75,P<0.001);而与甲状腺癌患者的年龄、性别、肿瘤大小、包膜是否受侵、淋巴结有无转移等临床病理因素无关。③在甲状腺癌组织中两型受体的表达呈正相关(r=0.77,P<0.001)。结论:TNFRp55和TNFRp75在甲状腺癌中协同高表达,参与了甲状腺癌的发生、发展过程。它们可以作为甲状腺癌诊断与鉴别诊断的病理学指标之一,但不能用来评估甲状腺癌的生物学行为及预后。
Objective:To investigate the expression of tumor necrosis factor receptor(TNFR) p55 and p75 in thyroid carcinoma and their relations with clinicopathologic factors, so as to study the role and significance of the two receptors in thyroid carcinoma tissues . Methods:SP immunohistochemical method was used to determine their expression of TNFRp55 and p75 in 41 specimens of thyroid cancerous tissues. Simultaneously 9 thyroid adenomas tissues and 7 normal thyroid tissues adjacent to the adenoma were regarded as the control group. Results:(1) The levels of TNFRp55 and p75 in thyroid carcinoma were significantly higher than those in the control group(P 〈 0. 001 ) ,but there was no significant difference for p55 and p75 between thyroid adenomas and normal thyroid tissues( P 〈 0. 001 ). (2)Their expression levels of TNFRp55 and p75 were closely related to pathologic histological types: they were higher in papillary thyroid carcinoma than those in follicular thyroid carcinomas( TNFRp55, P 〈 0.05 ;TNFRp75, P 〈 0. 001 ) , but they were not related to other clinicopathologic factors such as sex,age, the depth of invasion, lymphnode metastasis and the size of tumor. (3)Two types of TNFR turned out to have positive relations in thyroid carcinoma tissues(r = 0.77 ,P 〈 0. 001 ). Conclusion:TNFRp55 and p75 are highly synergetic expressed in thyroid carcinoma tissues, which are involved in the generation and development of the carcinogenesis of thyroid carcinoma, controlling the spread of papillary thyroid carcinoma. They are one of the pathological indexes for diagnosis and differential diagnosis of thyroid carcinoma, but are probably not used to assess the biological behaviors and prognoses of thyroid carcinoma.
出处
《华北国防医药》
2007年第1期8-10,F0002,共4页
Medical Journal of Beijing Military Region